Sana Biotechnology Inc (SANA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sana Biotechnology Inc (SANA) has a cash flow conversion efficiency ratio of -0.212x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.79 Million) by net assets ($154.57 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Sana Biotechnology Inc for the company's overall valuation and market capitalisation.
Sana Biotechnology Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Sana Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sana Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sana Biotechnology Inc ranked by their cash flow conversion efficiency. Explore SANA operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hanmi Financial Corporation
NASDAQ:HAFC
|
-0.011x |
|
NTG Nordic Transport Group A/S
CO:NTG
|
-0.002x |
|
Southside Bancshares, Inc.
NYSE:SBSI
|
0.057x |
|
Pacira BioSciences, Inc.
NASDAQ:PCRX
|
0.086x |
|
ArcherMind Technology Nanjing Co Ltd
SHE:300598
|
0.008x |
|
Jingjin Environmental Protection Co Ltd
SHG:603279
|
0.050x |
|
Hyosung TNC Corp
KO:298020
|
0.065x |
|
Piraeus Port Authority S.A
AT:PPA
|
0.158x |
Annual Cash Flow Conversion Efficiency for Sana Biotechnology Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Sana Biotechnology Inc from 2018 to 2025. View Sana Biotechnology Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $160.88 Million | $-143.83 Million | -0.894x | -0.36% |
| 2024-12-31 | $250.50 Million | $-223.15 Million | -0.891x | -1.00% |
| 2023-12-31 | $287.51 Million | $-253.58 Million | -0.882x | -51.84% |
| 2022-12-31 | $499.31 Million | $-290.05 Million | -0.581x | -68.56% |
| 2021-12-31 | $728.50 Million | $-251.05 Million | -0.345x | -205.19% |
| 2020-12-31 | $-421.18 Million | $-137.98 Million | 0.328x | -45.39% |
| 2019-12-31 | $-142.54 Million | $-85.50 Million | 0.600x | -41.38% |
| 2018-12-31 | $-13.19 Million | $-13.49 Million | 1.023x | -- |
About Sana Biotechnology Inc
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary… Read more